OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Carla Ferrell and Sista Strut 2026: Breast Cancer Awareness Mission

A New Chance to Prevent Recurrence: EU Approves Trastuzumab Deruxtecan for HER2-Positive Early Breast Cancer

Arun Azad: New TALAPRO-2 Data Highlight the Prognostic Value of ctDNA and CTCs in Prostate Cancer

Jeff Dunn on Cancer Equity: The Powerful Message Behind “Poverty Is a Carcinogen”

Top Gastroesophageal Cancer Updates From ESMO 2026

Oncology News, Insights, Stories by OncoDaily

Trastuzumab Deruxtecan
Breast Oncology

Trastuzumab Deruxtecan Secures EU Approval for Residual HER2-Positive Early Breast Cancer Following DESTINY-Breast05 Survival-Free Disease Benefit

FASCO- OncoDaily
Career Updates

FASCO 2027: Recognizing Dedication to Oncology

ASCO
Lung Oncology

ASCO 2026.3.4 Living Guideline: Lorlatinib Takes Priority in First-Line ALK-Positive NSCLC After Landmark Seven-Year CROWN Results

KEYFORM-007: Dual PD-1/LAG-3 Blockade in MSS Colorectal Cancer

200 Most Influential Cancer Papers Suggested by Sendurai Mani: HER2 Amplification

Martha Wanjiru: Honored With Kenya's National Hero Award for Cancer Advocacy

Nazik Hammad: From Describing the Crisis to Improved Data, Cancer Intelligence, and Action in Africa

Tsetsegsaikhan Batmunkh: Strengthening Disease Surveillance Through International Collaboration

Ruiling Yuan Appointed to the NCI Genitourinary Cancers Steering Committee’s Bladder Task Force - Self Regional Healthcare

Alejandra Mendez: Access to Lifesaving Radiotherapy Should Never Depend on Where a Child Lives

Voices
Kefah Mokbel

Kefah Mokbel: Does the Conventional Precursor Model Fully Explain DCIS?

Dario Trapani: How Can Global Collaboration Strengthen Acute Oncology Services?

BGIICC 2027 - She Is The World

Nazli Dizman: IMG Oncologists Highlight Pathways to Clinical Trial Participation

Shushan Hovsepyan: Pleased to Speak with Daniel Malarek About Leadership, Innovation and the Future of Cancer Care

Sumanta K. Pal: Congratulating Oncology Leaders on Earning the FASCO Distinction

Gianluca Franceschini: Making Quality of Life an Integral Part of Breast Cancer Treatment

FDA Approvals
CLL/SLL Pirtobrutinib

FDA Approves Pirtobrutinib for First-Line CLL/SLL Without 17p Deletion, a First for Non-Covalent BTK Inhibitors

Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications

Niklas Klümper: FDA Approves Belzutifan Plus Lenvatinib in Advanced ccRCC

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC

FDA Approves Curium’s Bexlutry (Lutetium Lu 177) for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

FDA Approves Floretyrosine F 18 for PET Imaging in Glioma

OncoDaily 100
100 Influential Women

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

Celebrities and Cancer

OncoCalendar

London Global Cancer Week - LGCW 2026

London Global Cancer Week

02 Nov
Global Cancer Week

Rare Gynecologic Cancers: Advancing Knowledge through Collaboration in Research and Clinical Care

The University of Texas MD Anderson Cancer Center

02 Nov
Rare Gynecologic Cancers

L’Oncodaily Session During London Cancer Week 2026

London Global Cancer Week

02 Nov
L’Oncodaily Session

Chromosomes in Crisis: From Chromosomal Instability to Catastrophes in Cancer Genomes

European Association for Cancer Research

03 Nov
Chromosomes in Crisis

GPON 2026 – Empowered Oncology Nurses Transform Cancer Care

Global Power of Oncology Nursing (GPON)

03 Nov
GPON 2026

SITC 2026

Society for Immunotherapy of Cancer

04 Nov
SITC

The ACCC Oncology Reimbursement Meeting – Reno

Association of Cancer Care Centers (ACCC)

04 Nov
ACCC Oncology

EORTC Genito-Urinary Cancer Group Autumn Meeting 2026

04 Nov
Genito-Urinary Cancer

Cancer Research UK Lung Cancer Centre of Excellence – Conference 2026

Cancer Research UK

04 Nov
Cancer Research UK

International Symposium of Critical Care in Cancer Patients

MD Anderson Cancer Center

04 Nov
International Symposium of Critical Care

European Course in Paediatric Radiology (ECPR) 2026 – Module 2

European Society of Paediatric Radiology (ESPR)

04 Nov
Paediatric Radiology

SLACOM – New and Innovative Strategies in Global Cancer Prevention: Ultrascreening and Risk Reduction Strategies

Latin American and Caribbean Society of Medical Oncology (SLACOM)

04 Nov
SLACOM

Immune-oncology
KEYFORM-007: Dual PD-1/LAG-3 Blockade in MSS Colorectal Cancer

KEYFORM-007: Dual PD-1/LAG-3 Blockade in MSS Colorectal Cancer

Agentic AI for Immune-Related Adverse Event Detection in Cancer Immunotherapy

Can the Tumor’s Own B Cells Reveal the Next Immunotherapy Target?

ESMO 2026: The Key Pembrolizumab Trials to Know

ESMO 2026: What’s New in Melanoma Immunotherapy?

KEYNOTE-C93 Trial: Pembrolizumab Versus Chemotherapy in dMMR Endometrial Cancer

MOIO Trial: Can Immunotherapy Be Given Less Frequently?

Gastrointestinal-Oncology
ESMO 2026 Gastroesophageal Cancer Updates

Top Gastroesophageal Cancer Updates From ESMO 2026

FOLFOX Chemotherapy: What It Is, Drugs, Uses, Cycles, and Side Effects

Phase III PRABITAS Trial: 14-Day vs 28-Day Lonsurf Plus Bevacizumab for Refractory mCRC

Key Updates in GI Oncology From ESMO 2026

NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer

OPTIMUM at ESMO 2026: Maintenance Olaparib With or Without Durvalumab in DDR-Mutated Advanced Biliary Tract Cancer

LEAP-012 at ESMO 2026: Long-Term OS Results With Lenvatinib Plus Pembrolizumab and TACE in HCC

Breast-Oncology
Trastuzumab Deruxtecan

Trastuzumab Deruxtecan Secures EU Approval for Residual HER2-Positive Early Breast Cancer Following DESTINY-Breast05 Survival-Free Disease Benefit

A New Chance to Prevent Recurrence: EU Approves Trastuzumab Deruxtecan for HER2-Positive Early Breast Cancer

Biomarker Landscape of ADCs and Bispecific Antibodies in Breast Cancer: The 2026 Clinical Trial Breakthroughs and Future of Precision Treatment

Inflammatory Breast Cancer in 2026: Evolving Diagnostic Criteria, Modern Trimodality Treatment, and the Challenge of Improving Survival

Triple-Negative Breast Cancer in Algeria in 2026: What Has Changed?

PHERGain Five-Year Results: Chemotherapy-Free HER2-Positive Breast Cancer Treatment Shows Durable Outcomes as ctDNA Refines Risk Assessment

HER2-Low Breast Cancer in Algeria: When a Low HER2 Signal Becomes Clinically Relevant

Lung-Oncology
Neoadjuvant Immunotherapy

Neoadjuvant Immunotherapy Linked to Improved Five-Year Survival in Resected NSCLC: Real-World Study Supports Long-Term Benefit Without Increased Surgical Morbidity

Biomarker Landscape of ADCs and Bispecific Antibodies in Lung Cancer: The 2026 Clinical Trial Evidence and Future of Precision Treatment

ASCO 2026.3.4 Living Guideline: Lorlatinib Takes Priority in First-Line ALK-Positive NSCLC After Landmark Seven-Year CROWN Results

KEYNOTE-867 Phase III: Pembrolizumab Plus SBRT Fails to Improve Event-Free Survival and Increases Severe Toxicity in Early-Stage NSCLC

What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment

ASTRIDE: Serplulimab Shows Numerically Longer Overall Survival Than Atezolizumab in US Patients With Extensive-Stage Small Cell Lung Cancer

SANOVO Phase III: Savolitinib Plus Osimertinib Significantly Prolongs First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC, With Strong Overall Survival Signal

OncoDaily TV
Dr Gevorg Tamamyan

Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg Tamamyan’s WHO DG Campaign

Rachel Purcell

Rachel Purcell Highlights New Zealand’s Nationwide Exercise Program for Bowel Cancer Patients

Alicia Fong

Alicia Fong: Exploring the Role of AI in Cancer Detection and Treatment

Dr Gevorg Tamamyan

“Stronger Regions, Stronger Countries…” – Dr Gevorg Tamamyan

Rejin Kebudi

“Diligent, Intelligent, Capable of Reaching Many Colleagues Globally ” – Rejin Kebudi, General Secretary of the International Society of Pediatric Oncology, about Dr Gevorg Tamamyan Upon His WHO DG Candidacy

Dr. Gevorg Tamamyan

“One of the Most Amazing and Truly Legendary Oncologists of Our Time” – Dr. Gevorg Tamamyan on Dr. Julie Gralow, Chief Medical Officer of ASCO

Dr Gevorg Tamamyan

“I Still Remember His Mentees That Spoke So Highly of Him… Having a Vision Means Investing in People That Will Make a Difference For the Years to Come” – Albanian Hematologist Liri Seraj Supports Dr Gevorg Tamamyan as WHO DG Candidate

World Radiotherapy Awareness Day

12 Countries, One Vision for the Future of Radiotherapy – World Radiotherapy Awareness Day

Bishal Gyawali

Erika Ruiz-Garcia Joins Bishal Gyawali on Grounded In Groundshot Podcast

Dr Gevorg Tamamyan

“One Planet is Not Enough For His Vision” – Dr Amalya Sargsyan Celebrates Her Mentor Dr Gevorg Tamamyan

Dr Gevorg Tamamyan

Renowned Surgeon and Inventor of Abraxane, Philanthropist Dr Patrick Soon-Shiong Endorses Dr Gevorg Tamamyan as WHO Director-General Candidate

Burnout

Oncology Beyond Guidelines: Burnout, Imposter Syndrome, Mentorship & Cancer Prevention with Imène Hadji

Not To Miss
Trastuzumab Deruxtecan

A New Chance to Prevent Recurrence: EU Approves Trastuzumab Deruxtecan for HER2-Positive Early Breast Cancer

Northeast GI Oncology Congress 2026: One Room, Many Perspectives

2026 Prix Galien Awards Recognize Major Advances in Cancer Treatment, Screening and Immunotherapy

2026 IBRI Global Forum: Connecting Science, Philanthropy, and Investment to Advance Medical Innovation

AbbVie Submits Etentamig BLA to FDA for Relapsed/Refractory Multiple Myeloma

25 Posts Not to Miss from ESMO Congress 2026: Day 5

25 Posts Not to Miss from ESMO Congress 2026: Day 4

OncoGrants
Cancer Research Grant

Elsa U. Pardee Foundation Cancer Research Grant

Graduate Hematology Award

ASH Graduate Hematology Award 2027

Biliary Cancer

2027 Conquer Cancer Young Investigator Award in Biliary Cancer

Technology Impact

CRI Technology Impact Award 2026–2027

Nanotechnology Cancer Interventions

NCI Toward Translation of Nanotechnology Cancer Interventions R01 Grant 2026

Upstream Research Center

Upstream Research Center Cancer Equity Pilot Grants 2027

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: Current Practice and Evolving Directions

CancerWorld

Oncologists
Kleida Mati

Kleida Mati

Oncologists Location Tirana, Albania
Dirk Arnold

Dirk Arnold

Oncologists Location Hamburg, Germany
Nita Radhakrishnan

Nita Radhakrishnan

Oncologists Location Noida, India
Lucia Masarova

Lucia Masarova

Oncologists Location Houston, USA
Sarfraz Ahmad

Sarfraz Ahmad

Oncologists Location Orlando, USA
Chi-kong Li

Li Chi-kong

Oncologists Location Hong Kong, China
Willem Lybaert

Willem Lybaert

Oncologists Location Sint-Niklaas, Belgium
El Hadji Daouda Niang

El Hadji Daouda Niang

Oncologists Location Dakar, Senegal

Drugs Atlas
Ofatumumab (Arzerra, Kesimpta): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Ofatumumab (Arzerra, Kesimpta) Nov 1, 2026 1:25 am
Obinutuzumab (Gazyva): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Obinutuzumab (Gazyva; Gazyvaro) Nov 1, 2026 1:23 am
Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer Sotorasib (Lumakras; AMG 510) Oct 31, 2026 6:38 am
Rituximab (Rituxan; MabThera): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in B-Cell Malignancies and Autoimmune Diseases Rituximab (Rituxan; MabThera) Oct 31, 2026 6:37 am
Adagrasib (Krazati; MRTX849): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Cancers Adagrasib (Krazati; MRTX849) Oct 30, 2026 12:57 am
Infigratinib (Truseltiq; BGJ398): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FGFR2-Rearranged Cholangiocarcinoma Infigratinib (Truseltiq; BGJ398) Oct 30, 2026 12:56 am
Futibatinib (Lytgobi): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma Futibatinib (Lytgobi) Oct 28, 2026 1:27 pm
Pemigatinib (Pemazyre): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FGFR-Driven Cancers and Myeloid/Lymphoid Neoplasms Pemigatinib (Pemazyre) Oct 28, 2026 1:02 am
Quizartinib (Vanflyta): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in FLT3-ITD–Positive Acute Myeloid Leukemia Quizartinib (Vanflyta) Oct 26, 2026 2:27 am
Gilteritinib (Xospata): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in Relapsed or Refractory FLT3-Mutated AML Gilteritinib (Xospata) Oct 26, 2026 1:34 am

OncoDaily Magazine

New Paper Alert
Partha Basu

Partha Basu's New Paper on the Potential of Handheld Ultrasound by Trained Nonradiologists

Gilberto Lopes

Gilberto Lopes Highlights Critical Links Between Lung Cancer Stigma, Depression and Anxiety

Ajay Aggarwal

Ajay Aggarwal: National Quality Improvement Can Transform Prostate Cancer Radiation Therapy Outcomes

Angela Mastronuzzi

Angela Mastronuzzi: M.A.P.-RT Validated in 268 Pediatric Patients to Improve Radiotherapy Planning and Support

Thor Halfdanarson

Thor Halfdanarson: Carcinoid Crisis Following PRRT May Be Less Common Than We Think

Ramji Srinivasan

Ramji Srinivasan Shares New Research on Sample Stabilization and Mass Cytometry in Oncology Trials

OncoDaily Medical Journal

GU Oncology

10.69690/ODMJ-001-1026-8269

Psychosocial burden and lifestyle impact in patients with renal cell carcinoma: a patient-reported outcomes analysis
Original Research

Pediatric Oncology

10.69690/ODMJ-001-1026-8309

Limited Prognostic Value of Baseline Curie Score in Children with High-Risk Neuroblastoma Treated with Contemporary Multi-modal Therapy: A Single-Center Retrospective Cohort Study
Original Research

Breast Cancer

10.69690/ODMJ-001-1026-8231

Variable-Volume Oncoplastic Reconstruction Using a Modified Würinger Central Pedicle Technique for Upper Quadrants Breast Cancer: a single-center experience
Original Research

GI Oncology

10.69690/ODMJ-001-1026-8138

Association of Alpha-Fetoprotein and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Camrelizumab Plus Rivoceranib vs Sorafenib: Post Hoc Exploratory Analysis of the CARES-310 Trial
Original Research

Oncology Nursing

10.69690/ODMJ-002-0926-8087

Risk of Atrial Fibrillation in Breast Cancer Patients Treated with Radiotherapy: A Scoping Review
Reviews

Pediatric Oncology

10.69690/ODMJ-011-0826-7849

Integrated Management of Endo and Exo-pelvic Sacrococcygeal Teratomas (Altman type III): Report of Two Cases
Case Reports & Case Series

Oncology Nursing

10.69690/ODMJ-001-0826-7778

Real-World Patterns of Immune-Related Toxicity in Gastrointestinal Cancer Patients Treated with Immunotherapy: A service evaluation
Original Research

Oncology Nursing

10.69690/ODMJ-002-0826-7795

Late presentation in cancer care: Implications for treatment and survival: A Narrative Review
Reviews